Literature DB >> 2844779

In vivo and in vitro autoprocessing of human immunodeficiency virus protease expressed in Escherichia coli.

C Z Giam1, I Boros.   

Abstract

The viral-specific protease of human immunodeficiency virus (HIV) has been expressed as a lacZ-protease fusion protein. This fusion protein contains protease cleavage sites at the gag/protease and protease/reverse transcriptase junctions and undergoes autoprocessing in vivo when expressed in Escherichia coli. The purified lacZ-protease fusion protein precursors also exhibit autoproteolytic activity in vitro. One cleavage product of the autoprocessing reactions is a 10-kDa protein that cross-reacts with peptide antisera prepared against the putative protease sequence. Consistent with the notion that HIV protease is an acid protease, its autoproteolytic activity is inhibited in alkaline buffers and by pepstatin A. The in vivo and in vitro autocleavage assays for HIV protease together with the overproduction of the protease should facilitate design and testing of therapeutic agents that inhibit gag-pol polyprotein processing and HIV virion maturation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2844779

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Novel method for probing the specificity binding profile of ligands: applications to HIV protease.

Authors:  Woody Sherman; Bruce Tidor
Journal:  Chem Biol Drug Des       Date:  2008-03-31       Impact factor: 2.817

Review 2.  Expression of virus-encoded proteinases: functional and structural similarities with cellular enzymes.

Authors:  W G Dougherty; B L Semler
Journal:  Microbiol Rev       Date:  1993-12

3.  Inhibition of XMRV and HIV-1 proteases by pepstatin A and acetyl-pepstatin.

Authors:  Krisztina Matúz; János Mótyán; Mi Li; Alexander Wlodawer; József Tőzsér
Journal:  FEBS J       Date:  2012-08-17       Impact factor: 5.542

4.  Autoprocessing: an essential step for the activation of HIV-1 protease.

Authors:  M Wan; M Takagi; B N Loh; X Z Xu; T Imanaka
Journal:  Biochem J       Date:  1996-06-01       Impact factor: 3.857

5.  Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors.

Authors:  G B Dreyer; B W Metcalf; T A Tomaszek; T J Carr; A C Chandler; L Hyland; S A Fakhoury; V W Magaard; M L Moore; J E Strickler
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

6.  Metalloendopeptidase QG. Isolation from Escherichia coli and characterization.

Authors:  L Polgár; A Szigetvári; M Löw; I Kóródi; E Balla
Journal:  Biochem J       Date:  1991-02-01       Impact factor: 3.857

7.  Mechanism of formation of human IgE-binding factors (soluble CD23): III. Evidence for a receptor (Fc epsilon RII)-associated proteolytic activity.

Authors:  M Letellier; T Nakajima; G Pulido-Cejudo; H Hofstetter; G Delespesse
Journal:  J Exp Med       Date:  1990-09-01       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.